I. Gilloteau
Novartis (Switzerland)(CH)Novartis (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Health Systems, Economic Evaluations, Quality of Life, Dermatology and Skin Diseases, Pharmaceutical studies and practices, Spondyloarthritis Studies and Treatments
Most-Cited Works
- → Quantifying the burden of informal caregiving for patients with cancer in Europe(2014)158 cited
- → Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study(2016)118 cited
- → Sleep Problems in Patients with Rheumatoid Arthritis(2013)108 cited
- → A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey(2018)87 cited
- → Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges(2014)81 cited
- → Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)(2018)74 cited
- → Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study(2017)68 cited
- → Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab(2017)56 cited
- → Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database(2017)54 cited
- → Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience(2015)35 cited